| Petaluma Valley Internal Medicine Inc | |
|
1250 Broadway Sonoma CA 95476-7500 | |
| (707) 262-6267 | |
| (707) 734-7766 |
| Full Name | Petaluma Valley Internal Medicine Inc |
|---|---|
| Speciality | Family Medicine |
| Location | 1250 Broadway, Sonoma, California |
| Authorized Official Name and Position | David G Streeter (PRESIDENT) |
| Authorized Official Contact | 7077651070 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Petaluma Valley Internal Medicine Inc 1310 Commerce St #b Petaluma CA 94954-1469 Ph: (707) 778-7862 | Petaluma Valley Internal Medicine Inc 1250 Broadway Sonoma CA 95476-7500 Ph: (707) 262-6267 |
| NPI Number | 1326089806 |
|---|---|
| Provider Enumeration Date | 06/08/2006 |
| Last Update Date | 12/12/2018 |
| Medicare PECOS PAC ID | 1355340225 |
|---|---|
| Medicare Enrollment ID | O20061204000633 |
News Archive
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor.
Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.
Worldwide, more than 50 million people are living with epilepsy. Treatment can cost as little as US$5 a year and eliminates seizures in about two-thirds of people.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326089806 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QA0505X | Family Medicine - Adult Medicine | G55098 (California) | Primary |
| Provider Name | David G Streeter |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1952342057 PECOS PAC ID: 2264490606 Enrollment ID: I20041230000651 |
News Archive
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor.
Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.
Worldwide, more than 50 million people are living with epilepsy. Treatment can cost as little as US$5 a year and eliminates seizures in about two-thirds of people.
› Verified 1 days ago
News Archive
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor.
Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.
Worldwide, more than 50 million people are living with epilepsy. Treatment can cost as little as US$5 a year and eliminates seizures in about two-thirds of people.
› Verified 1 days ago
Guy Delorefice M.d. Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 370 Perkins St, Sonoma, CA 95476 Phone: 707-938-1255 Fax: 707-938-2321 | |
Sonoma Family Practice Medical Associates P C Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 270 Perkins Street, Sonoma, CA 95476 Phone: 707-938-3131 Fax: 707-938-3678 | |
Sonoma Valley Community Health Center Mobile Van Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 19270 Sonoma Highway 12, Sonoma, CA 95476 Phone: 707-939-6070 Fax: 707-939-6077 | |
Walter C. Prehn M.d. A Professional Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 181 Andrieux St, Suite 206, Sonoma, CA 95476 Phone: 707-495-7762 Fax: 707-938-7337 | |
Sonoma Internal Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 670 Third St West, Sonoma, CA 95476 Phone: 707-938-5916 Fax: 707-938-8496 | |
Sound Inpatient Physicians Medical Group, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 347 Andrieux St, Sonoma, CA 95476 Phone: 707-935-5000 |